International Journal of Hematology

, Volume 106, Issue 4, pp 522–532 | Cite as

Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance

  • Kenji Ishitsuka
  • Satoshi Yurimoto
  • Kouichi Kawamura
  • Yukie Tsuji
  • Manabu Iwabuchi
  • Takeshi Takahashi
  • Kensei Tobinai
Original Article


We present the interim results of a postmarketing all-case surveillance study in patients with C–C chemokine receptor 4 (CCR4)-positive, relapsed or refractory adult T-cell leukemia–lymphoma (ATL) treated with the anti-CCR4 monoclonal antibody mogamulizumab since its 2012 launch in Japan. The safety and efficacy analysis populations comprised 484 and 442 patients, respectively. The ATL subtype was acute in 58.9% and lymphoma in 34.2% of patients. All patients were scheduled to receive intravenous infusions of mogamulizumab (1.0 mg/kg) once weekly for eight weeks, alone or in combination with other modalities. Adverse drug reactions (ADRs) were reported in 74.0% of patients, of which 35.7% were serious and 6.2% were fatal. The priority survey items of infusion-related reaction, skin disorder, infection, immune disorder, and tumor lysis syndrome were reported in 29.3, 34.3, 22.1, 3.5, and 2.5% of patients, respectively. Graft-versus-host disease was reported in 25/42 patients who received mogamulizumab before allogeneic hematopoietic stem cell transplantation. The best overall response rate was 57.7% overall, 57.5% in patients treated with mogamulizumab alone, and 58.2% in patients treated with combination therapy. This surveillance indicates that mogamulizumab shows acceptable tolerability in practice; however, because of the risk of serious/fatal ADRs, patients administered mogamulizumab should be carefully monitored.


Mogamulizumab Postmarketing surveillance ATL 



The authors wish to thank Denise Daley, MD, and Marion Barnett of Edanz Group Japan K.K. for providing medical writing support during the development of this manuscript, which was funded by Kyowa Hakko Kirin Co., Ltd.

Compliance with ethical standards

Conflict of interest

KI reports grants and personal fees from Kyowa Hakko Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Novartis, Eisai, and Taiho Pharmaceutical; personal fees from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical, and Pfizer; and grants from Yakult Pharmaceutical, MSD, and Japan Blood Products Organization, outside the submitted work. SY, KK, and YT are employees and stockholders of Kyowa Hakko Kirin. MI and TT are employees of Kyowa Hakko Kirin. KT reports grants and personal fees from Eisai, Takeda, Janssen, and Mundipharma; personal fees from Zenyaku Kogyo, and HUYA Bioscience International; and grants from Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical Celgene, GlaxoSmithKline, SERVIER, and Abbvie, outside the submitted work.


This study was funded by Kyowa Hakko Kirin Co., Ltd.


  1. 1.
    Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–92.PubMedGoogle Scholar
  2. 2.
    Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia–lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-cell leukemia. Oxford: Oxford University Press; 1994. p. 221–37.Google Scholar
  6. 6.
    Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia–lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625–34.PubMedGoogle Scholar
  10. 10.
    Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–82.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44 Suppl S1:1–58.CrossRefGoogle Scholar
  14. 14.
    JSHCT Monograph 2008 July (in Japanese).
  15. 15.
    Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Yonekura K, Tokunaga M, Kawakami N, Takeda K, Kanzaki T, Nakano N, et al. Cutaneous adverse reaction to mogamulizumab may indicate favourable prognosis in adult T-cell leukaemia-lymphoma. Acta Derm Venereol. doi: 10.2340/00015555-2421 (Epub ahead of print).
  17. 17.
    Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol. 2005;35:1722–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Shiratori S, Ohigashi H, Ito S, Kudo K, Adachi M, Minamimoto T, et al. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma. Hematol Oncol. 2017;35:138–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens–Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci. 2013;104:647–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Honda T, Hishizawa M, Kataoka TR, Ohmori K, Takaori-Kondo A, Miyachi Y, et al. Stevens-Johnson Syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient. Acta Derm Venereol. 2015;95:606–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Tanba K, Uoshima N, Uchiyama H, Kawata E, Isa R, Yamaguchi J, et al. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab. Ann Hematol. 2016;95:661–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Tay MR, Lim ST, Tao M, Quek RH, Tay K, Tan TT. Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy. Leuk Lymphoma. 2014;55:182–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Ishii Y, Itabashi M, Numata A, Yamamoto W, Motohashi K, Hagihara M, et al. Cytomegalovirus pneumonia after anti-CC-chemokine receptor 4 monoclonal antibody (mogamulizumab) therapy in an angioimmunoblastic T-cell lymphoma patient. Intern Med. 2016;55:673–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Ohyama Y, Kumode T, Eguchi G, Yamaguchi T, Maeda Y. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies. Ann Hematol. 2014;93:169–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Tamaki K, Kinjo T, Aoyama H, Tomoyose T, Nakachi S, Hanashiro T, et al. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia–lymphoma treated with mogamulizumab. J Infect Chemother. 2015;21:820–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Totani H, Kusumoto S, Ishida T, Masuda A, Yoshida T, Ito A, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy. Int J Hematol. 2015;101:398–404.CrossRefPubMedGoogle Scholar
  28. 28.
    Ifuku H, Kusumoto S, Tanaka Y, Totani H, Ishida T, Okada M, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia–lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45:1363–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Morichika K, Tomoyose T, Hanashiro T, Shimabukuro N, Tamaki K, Tedokon I, et al. Recurrence of psoriasis vulgaris accompanied by treatment with C–C chemokine receptor type 4 (CCR4) antibody (mogamulizumab) therapies in a patient with adult T cell leukemia/ lymphoma: insight into autoinflammatory diseases. Intern Med. 2016;55:1345–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1608–14.CrossRefPubMedGoogle Scholar
  32. 32.
    Haji S, Kiyasu J, Choi I, Suehiro Y, Toyoda K, Tsuda M, et al. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51:432–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51:725–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Ito Y, Miyamoto T, Chong Y, Aoki T, Kato K, Akashi K, et al. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transplant. 2013;48:998–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Yonekura K, Kanzaki T, Gunshin K, Kawakami N, Takatsuka Y, Nakano N, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia–lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41:239–44.CrossRefPubMedGoogle Scholar
  36. 36.
    Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22:886–94.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Kenji Ishitsuka
    • 1
  • Satoshi Yurimoto
    • 2
  • Kouichi Kawamura
    • 2
  • Yukie Tsuji
    • 3
  • Manabu Iwabuchi
    • 3
  • Takeshi Takahashi
    • 2
  • Kensei Tobinai
    • 4
  1. 1.Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental SciencesKagoshima UniversityKagoshimaJapan
  2. 2.Medical AffairsKyowa Hakko Kirin Co., Ltd.TokyoJapan
  3. 3.Pharmacovigilance and Quality Assurance DivisionKyowa Hakko Kirin Co., Ltd.TokyoJapan
  4. 4.Department of HematologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations